Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD1 | P21728 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | DRD5 | P21918 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.41 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773690 | 1.00 | DRD2 (0.51) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL1424878 | 0.86 | DRD2 (0.49) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL1424879 | 0.86 | DRD2 (0.49) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL12314080 | 0.84 | DRD2 (0.59) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL10295472 | 0.84 | DRD2 (0.59) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL1764638 | 0.79 | OPRM1 (0.54) | OPRM1OPRD1 | |
| SCHEMBL1764639 | 0.79 | OPRM1 (0.54) | OPRM1OPRD1 | |
| SCHEMBL10180323 | 0.77 | DRD2 (0.65) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL10180668 | 0.76 | DRD2 (0.63) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL1764998 | 0.75 | DRD2 (0.45) | DRD2DRD3OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210024515-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-01-28 | — | — | US | disclosed |
| US-10745394-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190308966-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-10 | — | — | US | disclosed |
| US-10426766-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-10377751-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190119267-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-04-25 | — | — | US | disclosed |
| US-10081626-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180200246-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-19 | — | — | US | disclosed |
| US-20100152199-A1 | HETEROARYLALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2195313-A1 | HETEROARYLALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| US-7691878-B2 | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100035921-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7622508-B2 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | THERAVANCE, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| WO-2009029253-A1 | HETEROARYLALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062335-A1 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062334-A1 | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20080207676-A1 | Crystalline forms of an 8-Azabicyclo(3.2.1)octane compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | disclosed |
| US-20070219278-A1 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308966-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD1 164/4885DRD4 380/4885 |
| US-20210024515-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD1 164/4885DRD4 380/4885 |
| US-10377751-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD1 164/4885DRD4 380/4885 |
| US-20190119267-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD1 164/4885DRD4 380/4885 |
| US-20180200246-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | OPRM1, SIGMAR1, OPRD1 | DRD2 587/4885DRD1 705/4885DRD4 1033/4885 |
| US-10426766-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | OPRM1, SIGMAR1, OPRD1 | DRD2 587/4885DRD1 705/4885DRD4 1033/4885 |
| US-10745394-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD1 164/4885DRD4 380/4885 |
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD1 164/4885DRD4 380/4885 |
| US-20080207676-A1 | Crystalline forms of an 8-Azabicyclo(3.2.1)octane compound | OPRM1, SIGMAR1, OPRD1 | DRD2 597/4885DRD1 728/4885DRD4 1070/4885 |
| US-10081626-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD1 164/4885DRD4 380/4885 |
| US-20100152199-A1 | HETEROARYLALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | DRD2 117/4885DRD1 190/4885DRD4 378/4885 |
| US-20090062335-A1 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRL1, OPRK1 | DRD2 154/4885DRD1 229/4885DRD4 408/4885 |
| US-20100035921-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD1 164/4885DRD4 380/4885 |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD1 164/4885DRD4 380/4885 |
| US-20090062334-A1 | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | DRD2 117/4885DRD1 190/4885DRD4 378/4885 |
| US-20070219278-A1 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | OPRM1, OPRD1, OGFR | DRD2 315/4885DRD1 375/4885DRD4 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.